Ensysce Biosciences (ENSC) Expected to Post Earnings on Friday

Ensysce Biosciences (NASDAQ:ENSC) will likely be issuing its Q3 2026 results on Friday, November 13th. Analysts expect the company to announce earnings of ($0.12) per share and revenue of $1.20 million for the quarter. Parties may visit the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, November 20, 2026 at 4:00 PM ET.

Ensysce Biosciences (NASDAQ:ENSC) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($0.20) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.20). Ensysce Biosciences had a negative return on equity of 2,550.30% and a negative net margin of 280.53%. The company had revenue of $1.16 million for the quarter, compared to the consensus estimate of $1.20 million. On average, analysts expect Ensysce Biosciences to post ($0.60) EPS for the current fiscal year and ($0.06) EPS for the next fiscal year.

Ensysce Biosciences Price Performance

NASDAQ ENSC opened at $0.36 on Wednesday. The stock has a market capitalization of $7.01 million, a P/E ratio of -0.13 and a beta of 1.11. The business has a 50 day simple moving average of $0.45 and a 200 day simple moving average of $0.42. Ensysce Biosciences has a one year low of $0.23 and a one year high of $2.17.

Analysts Set New Price Targets

Several research firms have recently weighed in on ENSC. Wall Street Zen upgraded shares of Ensysce Biosciences to a “hold” rating in a research note on Saturday, August 8th. Cantor Fitzgerald assumed coverage on shares of Ensysce Biosciences in a report on Tuesday, October 20th. They issued an “overweight” rating and a $2.00 target price on the stock. Finally, Weiss Ratings raised shares of Ensysce Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, October 30th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Ensysce Biosciences presently has a consensus rating of “Hold” and an average price target of $2.00.

Ensysce Biosciences Company Profile

Ensysce Biosciences, Inc. is a clinical-stage biotechnology company focused on developing prescription medicines designed to address opioid abuse, misuse and overdose. The company’s technology is intended to preserve the therapeutic benefits of opioid pain medicines while incorporating mechanisms that may reduce the risks associated with tampering or excessive dosing. Ensysce’s lead product candidate, PF614, is an investigational extended-release oxycodone prodrug designed to be activated in the gastrointestinal tract.